| Literature DB >> 34779336 |
Lingling Liu1, Kehang Xie2, Mengmeng Yin1, Xiaoqiu Chen1, Binhuan Chen1, Jianting Ke1, Cheng Wang1.
Abstract
BACKGROUND: Biomarkers of oxidative stress (OS) have been poorly explored in fungal peritonitis (FP). Potassium is a regulator of pro-oxidants and antioxidants. Albumin and vitamin B12 (B12) are vital antioxidant agents in the circulatory system. This study aimed to investigate the antioxidative role of serum potassium, albumin and B12 in FP.Entities:
Keywords: Potassium; albumin; fungal peritonitis; oxidative stress; vitamin B12
Mesh:
Substances:
Year: 2021 PMID: 34779336 PMCID: PMC8604478 DOI: 10.1080/07853890.2021.1999489
Source DB: PubMed Journal: Ann Med ISSN: 0785-3890 Impact factor: 4.709
Characteristics of patients with fungal and bacterial peritonitis (1:5 ratio matching).
| Characteristics | Fungal peritonitis | Bacterial peritonitis | Control | |||
|---|---|---|---|---|---|---|
| Median age (years) | 61.00 [46.00–71.50] | 50.00 [43.00–60.50] | 51.00 [42.75–61.00] | .053 | .024* | .921 |
| Female | 11/21 (52.38) | 54/105 (51.43) | 109/210 (51.90) | .936 | .967 | .936 |
| PD duration (months) | 43.00 [19.00–65.50] | 42.00 [12.00–72.00] | 18.00 [5.00–64.25] | .874 | .076 | .023* |
| Diabetes mellitus | 5/21 (23.81) | 14/105 (13.33) | 74/210 (35.24) | .312 | .293 | .000*** |
| Ischaemic heart disease | 7/21 (33.33) | 26/105 (24.76) | 16/210 (7.62) | .424 | .002** | .000*** |
| Chronic lung disease | 1/21 (4.76) | 4/105 (3.81) | 1/210 (0.48) | 1.000 | .174 | .044* |
| Cerebrovascular disease | 8/21 (38.10) | 16/105 (15.24) | 16/210 (7.62) | .029 | .000*** | .035* |
| Previous failed kidney transplant | 0/21 (0.00) | 3/105 (2.86) | 0/210 (0.00) | 1.000 | .036* | |
| Hypertension | 17/21 (80.95) | 90/105 (85.71) | 157/210 (74.76) | .522 | .530 | .026* |
| Hepatopathy | 3/21 (14.29) | 14/105 (13.33) | 23/210 (10.95) | 1.000 | .714 | .536 |
| Anuric | 13/21 (61.90) | 54/105 (51.43) | 68/210 (32.38) | .475 | .007** | .001** |
| Urine output (mL/day) | 0 [0–250.00] | 87.50 [0–650.00] | 500.00 [0–1000.00] | .072 | .000*** | .000*** |
| Exchange volume (L/day) | 8.00 [8.00–8.00] | 8.00 [7.00–8.00] | 8.00[6.00–10.00] | .803 | .975 | .674 |
| 1.5% DS exchange volume | 5.00 [2.50–6.00] | 6.00 [4.00–8.00] | 6.00 [4.00–8.00] | .424 | .053 | .083 |
| 2.5% DS exchange volume | 4.00 [0–6.00] | 2.00 [0–4.00] | 0 [0–4.00] | .297 | .053 | .186 |
| 4.25% DS | 0/21 (0.00) | 1/105 (0.95) | 4/210 (1.90) | 1.000 | 1.000 | .668 |
| Previous peritonitis episodes | 10/21 (47.62) | 26/105 (24.76) | .061 | |||
| Poor appetite | 15/21 (71.43) | 64/105 (60.95) | 30/210 (18.10) | .462 | .000*** | .000*** |
| Vomiting | 5/21 (23.81) | 22/105 (20.95) | 7/210 (3.33) | .774 | .002** | .000*** |
| Diarrhoea | 6/21 (28.57) | 27/105 (25.71) | 13/210 (6.19) | .789 | .003** | .000*** |
| Time between culture positivity and onset of symptoms (days) | 7.00 [7.00–15.50] | 4.00 [3.75–6.00] | .000*** | |||
| Hospital stay (days) | 22.00 [13.50–32.00] | 14.00 [13.00–19.00] | – | .013* | ||
| Aetiology ESRD | ||||||
| Chronic glomerulonephritis | 11/21 (52.38) | 68/105 (64.76) | 108/210 (51.43) | .327 | .934 | .025* |
| Diabetic mellitus | 2/21 (9.52) | 9/105 (8.57) | 42/210 (20.00) | 1.000 | .382 | .009** |
| Hypertension | 3/21 (14.29) | 5/105 (4.76) | 19/210 (9.05) | .128 | .432 | .177 |
| Polycystic kidney disease | 0/21 (0.00) | 7/105 (6.67) | 2/210 (0.95) | .600 | 1.000 | .007** |
| Systemic lupus erythematosus | 1/21 (4.76) | 1/105 (0.95) | 4/210 (1.90) | .307 | .382 | .668 |
| ANCA-relate glomerulonephritis | 2/21 (9.52) | 3/105 (2.86) | 0/210 (0.00) | .194 | .008** | .036* |
| Othera | 2/21 (9.52) | 12/105 (11.43) | 35/210 (16.67) | 1.000 | .542 | .219 |
| Accompanying medication | ||||||
| Diuretics or K+-binding resins | 0/21 (0.00) | 3/105 (2.86) | 7/210 (3.33) | 1.000 | 1.000 | 1.000 |
| RAAS inhibitors | 9/21 (42.86) | 46/105 (43.81) | 80/210 (38.10) | .936 | .669 | .329 |
| Under immunosuppressive therapy | 3/21 (14.29) | 6/105 (5.71) | 4/210 (1.90) | .172 | .018* | .089 |
| Previous antibiotic useb | 7/21 (33.33) | 11/105 (10.48) | 10/210 (4.76) | .013* | .000*** | .055 |
| Duration of antibiotic treatment (days) | 14.00 [12.00–14.00] | 14.00 [13.00–14.00] | 3.00 [3.00–5.00] | .954 | .002** | .002** |
| Outcome | ||||||
| Resolved (%) | 3/21 (14.29) | 88/105 (83.91) | .000*** | |||
| Catheter removal (%) | 12/21 (57.14) | 8/105 (7.62) | .000*** | |||
| Technique failure (%) | 18/21 (85.14) | 17/105 (16.19) | .000*** | |||
| Time to occurrence (days) | 8 [6–19] | 5 [1.5–17] | .229 | |||
| Death | 7/21 (33.33) | 5/105 (4.76)c | .001*** | |||
| Time to occurrence (days) | 17 [5.5–24.75] | 1 [1–1] | .400 | |||
| ICU-admission | 3/21 (14.29) | 1/105 (0.95) | .015* |
Abbreviations. PD: peritoneal dialysis; ESRD: end stage renal disease; DS: dialysis solution; RAAS: renin-angiotensin-aldosterone system.
aIncludes gouty nephropathy, renal calculi disease.
bWithin the preceding 3 months.
cIncludes 4 patients giving up treatment and without exact death date.
p1: FP vs. BP patients; p2: FP patients vs. control group; p3: BP patients vs. control group. The differences were considered significant if p-value < .05. ***p-value < .001; **p-value < .01; *p-value < .05.
Figure 1.(a, b) Microbiological findings in the FP and BP.
Clinical and laboratory details of the 21 fungal peritonitis.
| Remarks | ||
|---|---|---|
| Aged ≥ 65 years | 9 (42.86) | |
| PD duration ≥ 3 years | 13 (61.90) | |
| Cloudy effluent | 20 (95.24) | |
| Abdominal pain | 21 (100) | |
| Gastrointestinal symptoma | 19 (90.48) | |
| Fever | 13 (61.90) | |
| Hypotensionb | 8 (38.10) | |
| Peripheral WBC elevated | 7 (33.33%) | |
| Hypoalbuminemia | 21 (100) | Serum albumin reached severe low level (< 25 g/L) in 11 patients |
| Anaemia | 15 (71.43) | Serum haemoglobin ≤ 90g/L in 7 patients |
| With intestinal obstruction | 3 (14.29) | |
| Early antifungal administrationc | 9 (42.86) | |
| Initial treatment with IP fluconazole | 11 (52.38) | |
| Fluconazole as IV choice | 9 (42.86) | |
| Had oral antifungal administration | 14 (66.67) | |
| Had 2 antifungal drugs | 6 (28.57) |
Abbreviations. IP: intraperitoneal injection; IV: intravenous injection.
aIncludes nausea, vomiting, diarrhoea, or abnormal findings from stool examination.
bSBP ≤ 90 mmHg and (or) DBP ≤ 60 mmHg.
cAntifungal administration within 5 days after admission.
Figure 2.Comparison of serum levels of potassium, albumin and vitamin B12 in patients with fungal peritonitis, bacterial peritonitis, resolved outcome and technique failure. (a) Serum potassium (b) Serum albumin (c) Vitamin B12. ***p-value < .001; **p-value < .01; *p-value < .05.
Predictors of FP: univariate and multivariate binary logistic regression analysis.
| Univariate analysis | Multivariate analysis | |||||
|---|---|---|---|---|---|---|
| OR | 95% CI | OR | 95% CI | |||
| SBP (mmHg) | 1.032 | 1.011–1.052 | 1.017 | 0.991–1.045 | .207 | |
| DBP (mmHg) | 1.063 | 1.023–1.105 | 1.027 | 0.978–1.078 | .281 | |
| Cr (µmol/L) | 1.003 | 1.001–1.005 | 1.000 | 0.997–1.003 | .904 | |
| Potassium | 4.921 | 2.021–11.982 | 2.828 | 1.014–7.888 | ||
| Albumin (g/L) | 1.203 | 1.087–1.333 | 1.17 | 1.022–1.340 | ||
| B12 (pg/mL) | 1.001 | 1.000–1.002 | .141 | 1.001 | 1.000–1.003 | .080 |
ORs indicate the relative increased risk of FP with each change in SD (for SBP, DBP, Cr, potassium and albumin) when compared with BP. In multivariable regression analysis, these five variables were included in the same model.
Abbreviations. OR: odds ratio; CI: confidence interval.
The differences were considered significant if p-value < .05. ***p-value < .001; **p-value < .01; *p-value < .05.
Figure 3.ROC curves comparing the potential of different variables to predict FP and technique failure in peritonitis (a) The prediction of FP variables (b) Predictive ability of different variables of technique failure in peritonitis patients. Blue, albumin; red, potassium; green, vitamin B12; orange, reference line.